Upifitamab Rilsodotin
Ovarian Serous Adenocarcinoma
Explore 90 assets in Ovarian Serous Adenocarcinoma →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Mersana Therapeutics
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05329545CT.gov Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Serous Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Upifitamab Rilsodotin (this asset) | Mersana Therapeutics | P3 | B · 57 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Letrozole | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Olaparib | Institute of Cancer Research, United Kingdom | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Avutometinib | Verastem, Inc. | P3 | BB |
| Cediranib | National Cancer Institute (NCI) | P2/3 | BB |
| Cis-Diamminedichloroplatinum Ii | Genelux Corporation | P3 | BB |
+42 more in the Ovarian Serous Adenocarcinoma cohort
Other indications for Upifitamab Rilsodotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Cancer | — | P1/2 | CCC · 55 |
| Non-Small Cell Lung Carcinoma | — | P1/2 | CCC · 54 |
| Primary Peritoneal Carcinoma | — | P3 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Upifitamab Rilsodotin in Ovarian Serous Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/upifitamab-rilsodotin-ovarian-serous-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →